GPM Reminds Investors of the August 30th Deadline in the Class Action Lawsuit Against Lipocine Inc. and Encourages Investors
to Contact the Firm
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the August 30, 2016 deadline to file a lead
plaintiff motion in the class action filed on behalf of a class (the “Class”) of investors who purchased Lipocine Inc. (“Lipocine”
or the “Company”) (NASDAQ: LPCN) securities between February 27, 2015 and June 28, 2016, inclusive (the “Class Period”).
Throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse
facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements
and/or failed to disclose: (1) that the Company improperly designed and implemented its NDA for LPCN 1021; (2) that, as a result,
the FDA would deny or delay approval of the Company’s lead product candidate; (3) that, as a result of the foregoing, the Company’s
future revenues and viability would be jeopardized; and (4) that, as a result of the foregoing, the Company’s financial statements,
as well as Defendants’ statements about Lipocine’s business, operations, and prospects, were false and misleading and/or lacked a
reasonable basis.
If you purchased Lipocine shares, you may move the Court no later than August 30, 2016 to request appointment
as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at
310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and
number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Prongay & Murray LLP, Los Angeles
Casey Sadler, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160817005206/en/